ClinicalTrials.gg
TerminatedNCT05081180Updated Jul 29, 2026

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

A Phase 1 interventional study of Avelumab and Lenvatinib in Central Nervous System Tumors, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 9 sites in 4 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was stopped due to a lack of clear evidence of anti-tumor activity with the combination treatment in the participants treated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Central Nervous System Neoplasms with a site in France — 5 open to participants now, 15 under way, 2 of them phase 3. Central Nervous System Neoplasms · France.

Enrollment
40th of 41
17 · median 87
Started
2021
with 1 other
Phase 1
7 of 45
1 open now
Registered
39th of 45
by date

Among the 45 studies in Central Nervous System Neoplasms with a site in France, this one is the 40th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 1, and was the 39th registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

5 of the 45 studies in Central Nervous System Neoplasms with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Central Nervous System Neoplasms with a site in France, or all of them as a file.
02

Study summary

This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with Lenvatinib and determine the recommended Avelumab and Lenvatinib dose for expansion. Dose Expansion Part 2 will assess the efficacy of Avelumab in combination with Lenvatinib by Progression-free Survival in participants with pre-defined primary central nervous system (CNS) tumors.

03

Conditions studied

  • Central Nervous System Tumors

Keywords

  • Avelumab
  • Lenvatinib
  • Tumors
  • Pediatric CNS tumors
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed diagnosis of primary CNS as follows: a) Primary CNS tumors: the tumor should be considered high-grade histologically; prior radiotherapy is allowed; participants must have progressed after at least 1 prior systemic therapy, except for those with diffuse midline glioma with or without the H3 K27M mutation. b) Specific for participants with diffuse midline glioma with or without the H3 K27M mutation: prior radiotherapy is allowed; no more than 1 prior systemic therapy is allowed; participants with diffuse midline glioma with or without the H3 K27M mutation who have not received prior systemic therapy but have prior radiotherapy only are allowed to enroll
  • On screening scans, by RANO criteria
  • Participants must have a Lansky performance status >= 50 for age \<= 16 years or performance status >= 50 for age > 16 years at Screening
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with low-grade gliomas, for example but not limited to, subependymal giant cell astrocytoma, pilocytic astrocytoma and World Health organization (WHO) Grade 1 tumors
  • Participants demonstrating evidence of worsening of neurologic deficit within 1 week prior to initiation of study interventions
  • Participants with bulky tumor, defined as: a) Tumor with any evidence of uncal herniation or midline shift; b) Tumor with a diameter of > 4 centimeters (cm) in 1 dimension on T2/ fluid-attenuated inversion recovery (FLAIR) images; c) Tumor that in the opinion of the Investigator shows significant mass effect
  • Participants are not eligible if they experience uncontrolled seizures, defined as: a) Seizures requiring regular use of rescue medications. b) Seizures requiring increasing doses of antiepileptic medications. c) Seizures that in the opinion of the Investigator compromise the ability of the participant to tolerate study intervention or interfere with study procedures
  • Participants who have received major surgery (including but not limited to neurosurgical resection, brain , or radiation to the primary brain tumor) within 28 days prior to the first dose of study interventions
  • Participants with history of intracranial hemorrhage/spinal cord hemorrhage within 28 days prior to the first dose of study interventions
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Avelumab + Lenvatinib

    Drug: Avelumab · Drug: Lenvatinib

Interventions

  • Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.

  • Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Dose Escalation Part 1: Number of Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater Than or Equal to (>=) 3 Treatment-emergent Adverse Event (TEAEs) According to National Cancer Institute-CTCAE Version 5.0

    Time frame: up to 857 days

  2. Dose Escalation Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Baseline (Day 1) up to Day 28

  3. Dose Expansion Part 2: Progression-free Survival (PFS) According to Response Assessment in Neuro-Oncology (RANO) Criteria as Assessed by Investigators

    Time frame: until progressive disease or death, assessed up to Day 1534

Secondary outcomes

  1. Dose Escalation Part 1: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs), Adverse Event of Special Interest (AESIs), AEs Leading to Deaths

    Time frame: up to 876 days

  2. Dose Escalation Part 1: Number of Participants with Treatment-Emergent Adverse Events (AEs) Based on Severity According to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

    Time frame: up to 876 days

  3. Dose Escalation Part 1: Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters

    Time frame: up to 876 days

  4. Dose Escalation Part 1: Objective Response Rate (ORR) According to Response Assessment in Neuro-Oncology (RANO) Criteria as Assessed by Investigators

    Time frame: up to 876 days

  5. Dose Escalation Part 1: Duration of Response (DOR) According to Response Assessment in Neuro-Oncology (RANO) Criteria as Assessed by Investigators

    Time frame: up to 876 days

  6. Dose Escalation Part 1: Progression-Free Survival (PFS) According to Response Assessment in Neuro-Oncology (RANO) Criteria

    Time frame: until progressive disease or death, assessed up to 876 days

  7. Dose Escalation Part 1: Overall Survival (OS)

    Time frame: up to 876 days

  8. Dose Escalation Part 1: Serum Observed Concentration at End of Infusion (CEOI) of Avelumab

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately 876 days

  9. Dose Escalation Part 1: Area Under the Serum Concentration-Time Curve From the Time of Dosing 336 Hours (AUC0-336 [hr]) of Avelumab

    Time frame: Pre-dose up to 336 hours post-dose, assessed up to approximately 876 days

  10. Dose Escalation Part 1: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Avelumab

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately 876 days

  11. Dose Escalation Part 1: Maximum Observed Plasma Concentration (Cmax) of Lenvatinib

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately 876 days

  12. Dose Escalation Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Lenvatinib

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately 876 days

  13. Dose Escalation (Part 1): Area Under the Plasma Concentration-Time Curve From the Time of Dosing to 24 Hours (AUC0-24 [hr]) of Lenvatinib:

    Time frame: Pre-dose up to 24 hours post-dose, assessed up to approximately 876 days

  14. Dose Escalation Part 1: Immunogenicity of Avelumab as Measured by Antidrug Antibody (ADA) Assay

    Time frame: up to 876 days

  15. Dose Expansion Part 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs), Adverse Event of Special Interest (AESIs), AEs Leading to Deaths

    Time frame: up to Day 1534

  16. Dose Expansion Part 2: Number of Participants with Treatment-Emergent Adverse Events (AEs) Based on Severity According to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

    Time frame: up to Day 1534

  17. Dose Expansion Part 2: Number of Participants with Clinically Significant Changes in Laboratory Parameters

    Time frame: up to Day 1534

  18. Dose Expansion Part 2: Objective Response Rate (ORR) Rate According to Response Assessment in Neuro-Oncology (RANO) Criteria as Assessed by Investigators

    Time frame: up to Day 1534

  19. Dose Expansion Part 2: Duration of Response (DOR) According to Response Assessment in Neuro-Oncology (RANO) Criteria as Assessed by Investigators

    Time frame: up to Day 1534

  20. Dose Expansion Part 2: Overall Survival (OS)

    Time frame: up to Day 1534

  21. Dose Expansion Part 2: Serum Observed Concentration at End of Infusion (CEOI) of Avelumab

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately Day 1534

  22. Dose Expansion Part 2:Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Avelumab

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately Day 1534

  23. Dose Expansion Part 2: Maximum Observed Plasma Concentration (Cmax) of Lenvatinib

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately Day 1534

  24. Dose Expansion Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Lenvatinib

    Time frame: Pre-dose up to 30 days after last dose, assessed up to approximately Day 1534

  25. Dose Expansion Part 2: Immunogenicity of avelumab as measured by ADA assay

    Time frame: up to Day 1534

07

Study locations

9 sites
  • CHU Sainte-Justine
    Montreal, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique
    Angers, France
  • Hôpital de la Timone
    Marseille, France
  • Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris
    Paris, France
  • Universitaetsklinikum Hamburg Eppendorf
    Hamburg, Germany
  • Universitaetsklinikum Muenster
    Münster, Germany
  • Seoul National University Hospital
    Seoul, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Feb 2026, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Oct 18, 2021
StartActual
Dec 3, 2021
Primary completionActual
Feb 11, 2026
CompletionActual
Jun 9, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05081180
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Dec 3, 2021
Primary completion
Feb 11, 2026
Completion
Jun 9, 2026
Last update
Jul 29, 2026

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion